Bipolar Disorder Clinical Trial
Official title:
Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents
The objectives of this study are to determine whether this treatment may be useful for reducing cannabis consumption; reducing symptoms of bipolar mania; and weight mitigation therapy for individuals on psychopharmacotherapy.
The purpose of this research study is to study the effects (both good and bad) of combining
medicines, called quetiapine and topiramate, for treating your symptoms, and other children
and adolescents' symptoms, of bipolar mania (an illness with periods of elation, excessive
excitement, irritability, high energy, racing thoughts, poor sleep, poor judgment, reckless
behavior). It is estimated that 1% of the population of adolescents in the United States has
bipolar disorder. The purpose of this research study is also to study the effects (both good
and bad) of combining the same two medicines, quetiapine and topiramate, for reducing your
use, and other children and adolescents' use, of cannabis (commonly referred to as "pot"). It
is estimated that 30.5% of adolescents in the United States have used cannabis at least once
in their lifetime. Additionally, the purpose of this research is to look at how bipolar
disorder and cannabis use effects brain chemicals and function.
Quetiapine (marketed under the brand name Seroquel) has been approved by the FDA since 1997
to help adults who suffer from schizophrenia (an illness of feeling, thought, perception and
behavior). On January 12, 2004, the FDA approved quetiapine for the treatment of bipolar
symptoms in adults. As of December 2009, Quetiapine has now been approved by the FDA for use
in adolescents (13-17 years of age) for the treatment of schizophrenia and for the treatment
of manic episodes associated with bipolar I disorder in children and adolescents (10-17 years
of age). Bipolar disorder is an illness characterized by recurrent mood swings including
mania (i.e., periods of elation, excessive excitement, irritability, high energy, racing
thoughts, poor sleep, poor judgment, reckless behavior) and clinical depression (i.e., a
depressed mood, loss of interest in activities and disruption of sleep, appetite and energy).
This study is being carried out to see if quetiapine is effective and safe for treatment of
children and adolescents who have the symptoms of bipolar mania. This study is also being
carried out to see if quetiapine, in combination with topiramate, will further reduce bipolar
mania and reduce cannabis use.
As of December 2, 2009, the US Food and Drug Administration (FDA) approved SEROQUEL
(quetiapine fumarate) tablets for the treatment of schizophrenia in adolescents (13-17 years
of age) as monotherapy, and for the acute treatment of manic episodes associated with bipolar
I disorder in children and adolescents (10-17 years of age), both as monotherapy and as an
adjunct to lithium or divalproex.
Topiramate (marketed under the brand name Topamax) is approved by the U.S. FDA for the
prevention of migraine headaches in adults. The FDA has also approved topiramate for epilepsy
(a seizure disorder) and for use as adjunctive therapy (meaning in combination with other
medicines) for partial onset seizures in adults. Topiramate is not approved by the FDA for
use in adults or for use in children and adolescents who have bipolar disorder. This study is
being done to see if topiramate, in combination with quetiapine, will reduce bipolar mania
and reduce cannabis use.
The FDA has declared research studies with MRI field strengths up to and including 8 Tesla (a
measure of field strength) as non-significant risk. This research study uses an MRI with a
field strength of 4 Tesla.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT02855762 -
Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder
|
N/A | |
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Completed |
NCT02513654 -
Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects
|
Phase 1 | |
Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
Completed |
NCT02304432 -
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
|
Early Phase 1 | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT02212041 -
Electronic Cigarettes in Smokers With Mental Illness
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Not yet recruiting |
NCT04432116 -
Time and Virtual Reality in Schizophrenia and Bipolar Disorder
|
N/A | |
Completed |
NCT02970721 -
Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
|
||
Terminated |
NCT02893371 -
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
|
||
Terminated |
NCT02909504 -
Gao NARASD Lithium Study
|
Phase 4 | |
Recruiting |
NCT03088657 -
Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
|
||
Recruiting |
NCT02481245 -
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
|
Phase 2 |